## Why "Administer a second dose of oxytocin 10 IU IM and perform controlled cord traction with counter-pressure on the uterus" is right Stage 3 of labor (marked **C** in the diagram) normally lasts 5–30 minutes. At 35 minutes, this patient has a **prolonged third stage**, which is a major risk factor for postpartum hemorrhage (PPH)—the leading cause of maternal mortality globally. The clinical anchor mandates that active management of third stage labor (AMTSL) reduces PPH risk by approximately 50%. The three components of AMTSL are: (1) prophylactic uterotonic immediately after delivery of the anterior shoulder (oxytocin 10 IU IM is first-line per WHO), (2) controlled cord traction with counter-pressure on the uterus (Brandt-Andrews maneuver) once signs of placental separation appear, and (3) uterine massage after placental delivery. At 35 minutes with no placental delivery, a second dose of oxytocin combined with controlled cord traction is the evidence-based next step to expedite placental delivery and prevent hemorrhage. [Williams Obstetrics 26e; FIGO 2018 Guidelines] ## Why each distractor is wrong - **"Wait passively for spontaneous placental delivery, as prolonged third stage is normal in primigravidas"**: Prolonged third stage (>30 min) is NOT normal and is explicitly a major risk factor for PPH. Passive management increases hemorrhage risk; active management is mandated. Expectant management is contraindicated once the 30-minute threshold is crossed. - **"Perform immediate manual removal of placenta under anesthesia"**: Manual removal of placenta is reserved for retained placenta (typically defined as non-delivery after 30–60 minutes of active management) or when placental separation signs are absent and bleeding is uncontrolled. At 35 minutes with active management just initiated, manual removal is premature and carries higher morbidity than continued AMTSL. - **"Administer ergot alkaloid (methylergonovine) 0.2 mg IM as the first-line uterotonic"**: While ergot alkaloids are effective uterotonics, oxytocin 10 IU IM is the WHO first-line uterotonic for third stage management. Ergot is contraindicated in hypertension and is reserved as a second-line agent or for cases where oxytocin is unavailable. **High-Yield:** Prolonged third stage (>30 min) = major PPH risk; AMTSL (oxytocin + controlled cord traction + uterine massage) reduces PPH by ~50% and is the standard of care. [cite: Williams Obstetrics 26e; FIGO 2018 Guidelines]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.